Compare BVS & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BVS | VNDA |
|---|---|---|
| Founded | 2011 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 617.1M | 474.0M |
| IPO Year | 2016 | 2005 |
| Metric | BVS | VNDA |
|---|---|---|
| Price | $9.97 | $7.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $14.00 | ★ $14.90 |
| AVG Volume (30 Days) | 416.1K | ★ 1.5M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 163.46 | N/A |
| EPS | ★ 0.33 | N/A |
| Revenue | ★ $568,087,000.00 | $216,105,000.00 |
| Revenue This Year | $7.52 | $21.35 |
| Revenue Next Year | $7.06 | $37.40 |
| P/E Ratio | $29.97 | ★ N/A |
| Revenue Growth | N/A | ★ 8.72 |
| 52 Week Low | $5.81 | $3.81 |
| 52 Week High | $9.98 | $9.91 |
| Indicator | BVS | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 69.02 | 47.26 |
| Support Level | $8.43 | $7.12 |
| Resistance Level | N/A | $8.29 |
| Average True Range (ATR) | 0.35 | 0.33 |
| MACD | 0.05 | 0.02 |
| Stochastic Oscillator | 100.00 | 58.20 |
Bioventus Inc is a medical device company focused on developing and commercializing products to relieve pain and address musculoskeletal conditions. The company operates through two reporting segments, U.S. and International, and its product portfolio is organized into three main business areas: Pain Treatments, Surgical Solutions, and Restorative Therapies, offering products such as hyaluronic acid injections for osteoarthritis, peripheral nerve stimulation devices, bone graft substitutes, and ultrasound-based fracture healing therapies.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.